Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.68 |
| ▸ | LSS | P48449 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28251766 | 0.96 | P2RX7 (0.64) | P2RX7LSSMAOANOTUMKDM4E | |
| SCHEMBL14736049 | 0.85 | P2RX7 (0.64) | P2RX7LSSMAOANOTUMKDM4E | |
| SCHEMBL27866047 | 0.81 | P2RX7 (0.68) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL12146363 | 0.81 | P2RX7 (0.68) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL1514733 | 0.81 | P2RX7 (0.68) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL14736048 | 0.78 | P2RX7 (0.63) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL9963336 | 0.77 | P2RX7 (0.62) | P2RX7LSSMAOAKDM4EHPGD | |
| SCHEMBL11747736 | 0.77 | P2RX7 (0.62) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL5294250 | 0.75 | P2RX7 (0.59) | P2RX7LSSKDM4EHPGDHSD17B10 | |
| SCHEMBL10310331 | 0.75 | P2RX7 (0.59) | P2RX7LSSKDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| EP-3938362-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-19 | — | — | EP | disclosed |
| CN-113710667-A | Fused cyclic pyrimidinone derivatives for the treatment of HBV infection or HBV induced diseases | 爱尔兰詹森科学公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2020-04-28 | — | — | US | disclosed |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2019-01-08 | — | — | US | disclosed |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2019-01-03 | — | — | US | disclosed |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-09-04 | — | — | US | disclosed |
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-06-21 | — | — | US | disclosed |
| US-9944640-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2018-04-17 | — | — | US | disclosed |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-07-13 | — | — | US | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| US-9604937-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-03-28 | — | — | US | disclosed |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2016-01-07 | — | — | US | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170929-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | DPYD, MTHFD1, TYMS | P2RX7 3114/4885LSS 4056/4885MAOA 3804/4885 |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | DPYD, MTHFD1, TYMS | P2RX7 3221/4885LSS 4012/4885MAOA 3584/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | P2RX7 997/4885LSS 1857/4885MAOA 1923/4885 |
| US-10174029-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | DPYD, MTHFD1, TYMS | P2RX7 3114/4885LSS 4056/4885MAOA 3804/4885 |
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | P2RX7 3906/4885LSS 98/4885MAOA 3054/4885 |
| US-20190000856-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | P2RX7 3335/4885LSS 3090/4885MAOA 4459/4885 |
| US-10632125-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | P2RX7 3335/4885LSS 3090/4885MAOA 4459/4885 |
| US-20170196873-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | MTHFD1, MTHFD2, TPMT | P2RX7 3335/4885LSS 3090/4885MAOA 4459/4885 |
| US-10064869-B2 | MTH1 inhibitors for treatment of inflammatory and autoimmune conditions | MTHFD1, MTHFD2, TPMT | P2RX7 3335/4885LSS 3090/4885MAOA 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.